San Jose, CA, April 11, 2008 --(
PR.com)-- Continuing in its commitment to developing new MMP solutions, AnaSpec has introduced its newest MMP antibodies – anti-MMP-8 (hinge), anti-MMP-9 (hinge), anti-MMP-11 (hinge), anti-MMP-13 (IN) and anti-MMP-28 (IN) antibodies.
Matrix metalloproteinases (MMP) belong to a family of proteolytic enzymes capable of degrading connective tissue components, making them important in embryonic development, apoptosis, tumor cell growth, invasion, metastasis, angiogenesis and wound healing. Substrates for MMPs include cell adhesion molecules, growth factors, cytokines, and proteases. Immunogens used to develop these antibodies include synthetic peptides, recombinant and native proteins. Applications include western blot, IHC, IP, and ELISA.
Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry.
For more information, visit www.anaspec.com
###
